Cargando…

HLA-DQ antibodies in alloimmunity, what makes them different?

PURPOSE OF REVIEW: De novo HLA-DQ antibodies are the most frequently observed after solid-organ allotransplantation; and are associated with the worse adverse graft outcomes compared with all other HLA antibodies. However, the biological explanation for this observation is not yet known. Herein, we...

Descripción completa

Detalles Bibliográficos
Autores principales: Meneghini, Maria, Tambur, Anat R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10487393/
https://www.ncbi.nlm.nih.gov/pubmed/37219535
http://dx.doi.org/10.1097/MOT.0000000000001079
_version_ 1785103228402139136
author Meneghini, Maria
Tambur, Anat R.
author_facet Meneghini, Maria
Tambur, Anat R.
author_sort Meneghini, Maria
collection PubMed
description PURPOSE OF REVIEW: De novo HLA-DQ antibodies are the most frequently observed after solid-organ allotransplantation; and are associated with the worse adverse graft outcomes compared with all other HLA antibodies. However, the biological explanation for this observation is not yet known. Herein, we examine unique characteristics of alloimmunity directed specifically against HLA-DQ molecules. RECENT FINDINGS: While investigators attempted to decipher functional properties of HLA class II antigens that may explain their immunogenicity and pathogenicity, most early studies focused on the more expressed molecule – HLA-DR. We here summarize up-to-date literature documenting specific features of HLA-DQ, as compared to other class II HLA antigens. Structural and cell-surface expression differences have been noted on various cell types. Some evidence suggests variations in antigen-presenting function and intracellular activation pathways after antigen/antibody interaction. SUMMARY: The clinical effects of donor-recipient incompatibility at HLA-DQ, the risk of generating de novo antibodies leading to rejection, and the inferior graft outcomes indicate increased immunogenicity and pathogenicity that is unique to this HLA antigen. Clearly, knowledge generated for HLA-DR cannot be applied interchangeably. Deeper understanding of features unique to HLA-DQ may support the generation of targeted preventive-therapeutic strategies and ultimately improve solid-organ transplant outcomes.
format Online
Article
Text
id pubmed-10487393
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-104873932023-09-09 HLA-DQ antibodies in alloimmunity, what makes them different? Meneghini, Maria Tambur, Anat R. Curr Opin Organ Transplant HUMORAL IMMUNITY IN SOLID ORGAN TRANSPLANTATION: Edited by Paolo Cravedi PURPOSE OF REVIEW: De novo HLA-DQ antibodies are the most frequently observed after solid-organ allotransplantation; and are associated with the worse adverse graft outcomes compared with all other HLA antibodies. However, the biological explanation for this observation is not yet known. Herein, we examine unique characteristics of alloimmunity directed specifically against HLA-DQ molecules. RECENT FINDINGS: While investigators attempted to decipher functional properties of HLA class II antigens that may explain their immunogenicity and pathogenicity, most early studies focused on the more expressed molecule – HLA-DR. We here summarize up-to-date literature documenting specific features of HLA-DQ, as compared to other class II HLA antigens. Structural and cell-surface expression differences have been noted on various cell types. Some evidence suggests variations in antigen-presenting function and intracellular activation pathways after antigen/antibody interaction. SUMMARY: The clinical effects of donor-recipient incompatibility at HLA-DQ, the risk of generating de novo antibodies leading to rejection, and the inferior graft outcomes indicate increased immunogenicity and pathogenicity that is unique to this HLA antigen. Clearly, knowledge generated for HLA-DR cannot be applied interchangeably. Deeper understanding of features unique to HLA-DQ may support the generation of targeted preventive-therapeutic strategies and ultimately improve solid-organ transplant outcomes. Lippincott Williams & Wilkins 2023-10 2023-05-23 /pmc/articles/PMC10487393/ /pubmed/37219535 http://dx.doi.org/10.1097/MOT.0000000000001079 Text en Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/)
spellingShingle HUMORAL IMMUNITY IN SOLID ORGAN TRANSPLANTATION: Edited by Paolo Cravedi
Meneghini, Maria
Tambur, Anat R.
HLA-DQ antibodies in alloimmunity, what makes them different?
title HLA-DQ antibodies in alloimmunity, what makes them different?
title_full HLA-DQ antibodies in alloimmunity, what makes them different?
title_fullStr HLA-DQ antibodies in alloimmunity, what makes them different?
title_full_unstemmed HLA-DQ antibodies in alloimmunity, what makes them different?
title_short HLA-DQ antibodies in alloimmunity, what makes them different?
title_sort hla-dq antibodies in alloimmunity, what makes them different?
topic HUMORAL IMMUNITY IN SOLID ORGAN TRANSPLANTATION: Edited by Paolo Cravedi
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10487393/
https://www.ncbi.nlm.nih.gov/pubmed/37219535
http://dx.doi.org/10.1097/MOT.0000000000001079
work_keys_str_mv AT meneghinimaria hladqantibodiesinalloimmunitywhatmakesthemdifferent
AT tamburanatr hladqantibodiesinalloimmunitywhatmakesthemdifferent